| Name | Title | Contact Details |
|---|---|---|
Christen DiPetrillo |
Director of Intellectual Property | Profile |
Irene Pleasure |
Senior Vice President, General Counsel | Profile |
Stephen Leanos |
Senior Director, Legal | Profile |
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles.
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease.
Kinsbursky Brothers is a Anaheim, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform.